Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Adds Neuro-enhancing Therapies to 6 KWC Clinics, With Plans to Expand Across the Nation

  • Delic Holdings Corp works to develop novel solutions for hard-to-treat mental and emotional disorders
  • The company’s Ketamine Wellness Centers (“KWC”) clinical subsidiary recently announced the addition of NAD+ (nicotinamide adenine dinucleotide) infusion therapies as a means of boosting natural energy stores and immunity, brain and DNA function, and cell communication
  • The NAD+ therapies will launch in six of KWC’s clinics on May 9 — in Jacksonville, Fla.; Houston and Dallas, Texas; Salt Lake City, Utah; Las Vegas, Nev.; and Tucson, Ariz.
  • KWC intends to expand the treatment to additional clinics across the country in the coming months

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties utilizing a toolbox of innovative, therapeutic treatments based in psychedelic substances. 

The company’s Delic Labs scientific research subsidiary aims to develop IP of the highest quality, while affiliated clinics work to administer the psychedelic treatments under…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.